AKERMIN

Akermin’s core technology is a unique methodology to protect and enable robust enzyme performance in harsh industrial environments. The company’s focus is to develop an economical enzyme driven system to capture greenhouse gas in large industrial processes such as flue gas from power plants. During 2009, the approach was experimentally confirmed in the lab. The primary goal in 2010 is to build, test and optimize bench scale prototypes to establish systems design and confirm economic advantage. Akermin will continue the development of its biofuel cell prototype with testing to establish final design for the military in 2010.http://www.akermin.com Arch Angels Investment: $2,750,000

APPISTRY

Appistry’s products provide a cloud computing platform to deliver transparent scalability, application-level fault tolerance, and automated management for new and existing applications. With a broad customer list that includes FedEx, government intelligence agencies, State Street Bank, GlaxoSmithKline and others, Appistry’s platform supports mission-critical applications for some of the world’s leading organizations. Appistry’s 2009 revenue doubled compared to 2008. Appistry greatly enhanced its product line in 2009 with the addition of CloudIQ Manager, which allows customers to easily deploy and manage cloud applications. Appistry expects to announce by spring 2010 the release of CloudIQ Storage providing dynamically scalable, fault-tolerant and low cost file storage.www.appistry.com Arch Angels Investment: $1,950,000

CARDIALEN, INC.

picture-3.pngCardiaLen develops low-energy implantable atrial cardioverters for pain-free cardioversion of atrial fibrillation (AF). It will commercialize these devices to address unmet needs in AF therapy, improve outcomes and reduce stroke and heart failure risk. Low-energy, pain-free cardioversion offers significant benefits in ventricular fibrillation (VF) also but, given the strong position of high-voltage implantable VF devices, it will develop such VF applications in alliances only. Pain-free atrial cardioverters will add a new segment to the $12B global market for implantable cardiac rhythm devices. They will add a new option for drug refractory and persistent AF patients unsuited to catheter ablation. Physicians and insurers will enjoy shorter procedures, favorable reimbursement and lower costs.http://www.cardialen.com Arch Angels Investment: $175,000

CLEARENT

ClearentClearent is using state-of-the-art technology to revolutionize the payments processing industry. Using proprietary software infrastructure, Clearent is able to deliver a highly reliable, highly scalable system built on commodity hardware that results in lower capital, development and operations cost. Clearent has 29 employees and did $8 million in 2009 revenue, representing year-over-year growth in excess of 115 percent. Clearent sells its services through banks and independent sales organizations.www.clearent.com Arch Angels Investment: $1,000,000

COGNO

CognoCogno is a multimedia children’s brand that inspires kids ages 7-13 to think critically and imaginatively in science and math. Cogno’s brand position has been described as “Star Wars meets the Magic School Bus.” Bill Nye The Science Guy® wrote a foreword for the Cogno novel series, and the business was featured in the Wall Street Journal. After winning 25 national product awards, the company is pursuing IP licensing in television, books and virtual world licensing. The company continues to grow its internationally syndicated puzzlers for classrooms, now reaching over 450,000 children weekly.www.cogno.com Arch Angel Investment: $240,000

DIVERGENCE, INC.

divergence_300dpi_logo.jpgDivergence is an agricultural biotechnology company focusing on discovery and early-stage product development. Its emphasis has been on parasitic infections. In the past year, Divergence has had its third year of successful field trials with its lead nematicidal chemistry and also had very positive results in trials of its transgenic nematode-resistant technology. Divergence also validated its Harvest® platform for the discovery of novel agrichemistry with the discovery of new classes of fungicidal chemistry.www.divergence.com Arch Angels Investment: $127,500

EDUNN BIOTECHNOLOGY, INC.

Edunn BiotechnologyEdunn Biotechnology, Inc. is developing unique oligonucleotide drugs to treat central nervous system diseases. Edunn’s OL-1 drug is designed to cure Alzheimer’s disease and to treat Down syndrome. It is highly selective and has shown significant activity and safety in multiple preclinical models. The Company is waiting to hear the results of a multi-million dollar grant submission to NIH under the RAID Program. If Edunn receives the grant it would be within $1M of starting its Alzheimer’s Clinical Trial.www.edunn.com Arch Angels Investment: $405,000

ENDOSTIM

picture-4.pngEndostim’s mission is to develop and commercialize a new treatment for Gastroesophageal Reflux Disease, Urinary Urge Incontinence and other sphincter related disorders. The company’s proprietary solution is the first to offer restoration of physiological sphincter function through neurostimulation, using a miniaturized, wireless microstimulator placed in the sphincter to address these disorders. In contrast to current approaches, Endostim’s solution could be performed as an outpatient procedure and promises to address these diseases less invasively and at lower cost. To date, Endostim has validated its technology and clinical approach through a successful first-in-man acute clinical study and intends to proceed with sub-acute and chronic human trials to prepare for regulatory approval.Arch Angels Investment: $60,000

GLOBAL VELOCITY

Traditional software-based solutions can’t provide the depth, speed, scale or application-scope needed to meet the escalating cyber security threat. Global Velocity has therefore developed the world’s first wire-speed networking platform that supports multiple cyber security solutions. The company’s first commercial product, GV-2010, which launched in 2009, offers three integrated cyber security applications - Data Loss Prevention, Application Control and Pattern Recognition - in one extremely high-speed device. The GV-2010 is a paradigm shift for cyber security. It also reduces cost and risk. This past year Global Velocity also signed its first commercial and federal resellers and has had several patents issued. Market ramp up is now underway.www.globalvelocity.com Arch Angels Investment: $511,200

LORI COULTER

Lori CoulterLori Coulter developed the TrueMeasure line of apparel. Rooted in technology and fashion, Coulter’s line features wearable swimwear that flatters the figure, fits and boosts self-esteem. Coulter utilizes the TrueMeasure fit system, a process that employs light and camera-based technology; the [TC]2 3D Body Scanner, a proprietary ordering and fulfillment system, and automated CAD technology. The scanner measures the entire human body in less than 12 seconds and produces a true-to-scale 3D body model within a minute that is more accurate and consistent than measurements taken by a trained professional. The technology-based approach to fashion is an innovation in the retail industry with automated customization and rapid turnaround times. Lori Coulter Made-to-Order Swimwear launched at select Macy’s locations in 2007 and launched a custom wholesale business targeting resorts, pageants and branded products in 2008.www.loricoulter.com Arch Angels Investment: $360,000

MEDIA CONVERGANCE GROUP, INC. (Newsy.com)

NewsyMedia Convergence Group, Inc. is developing multiple businesses and revenue streams generated from a converged, digital newsroom that monitors, synthesizes and presents world news coverage. Although access to news sources is abundant, most consumers consider the news media to be biased. The consumer lacks a convenient and coherent way to comprehend, synthesize and gain understanding. In 2009 the company launched a successful mobile app for the iPhone, Intel Netbook and Android platforms as well as reconfigured its website to improve user engagement. The company expects to complete a $2M round of funding in 2010, secure its first paid test for a content licensing agreement, and launch an iPad app.http://www.newsy.com Arch Angels Investment amount: $175,000

SEQUOIA SCIENCES

Sequoia Sciences is a pharmaceutical company commercializing new medicines to treat bacterial infections. Programs consist of small molecules targeting the lung infections of cystic fibrosis patients and MRSA infections, and vaccines for the treatment of recurrent urinary tract infections. Sequoia also has an unparalleled collection of structurally diverse natural product compounds isolated from plants collected by the Missouri Botanical Garden. In 2009, Sequoia conducted a very successful large animal trial with its UTI compound and completed most of the pre-IND work to start clinical trials on its UTI compound in late 2010. Sequoia also received a NIH cancer grant and found a number of novel and exciting cancer compounds. It anticipates receiving a multi-million dollar NCI grant in 2010.www.sequoiasciences.com Arch Angel Investment: $6,360,000

SOMARK INNOVATIONS, INC

SomarkSOMARK’s goal is to improve life sciences research processes with an advanced lab-animal identification system. A more reliable and more humane ID system can provide higher quality preclinical data that can translate into safer treatments and a shorter development period. SOMARK wants to help researchers create safer, cheaper and more effective treatments. In 2009, SOMARK raised the company’s first round of institutional capital and achieved a successful proof-of-concept demonstration. In 2010, the company is looking to start a successful customer pilot, secure purchase orders, commence manufacturing and realize the company’s first revenues.www.somarkinnovations.com Arch Angels Investment: $554,000

TERAVISTA SYSTEMS

TeraVista SystemsTeraVista Systems provides corporations with a unique toolset of technologies that streamline their environmental and energy practices, thereby saving time and money. Its patent-pending CarbonTrax software is designed to automate the verification, validation and aggregation of carbon credits for all aggregation companies and financial institutions. Only 10 percent of current credits are being spot-validated, but CarbonTrax solves this problem through remote sensing technologies that allow for 90 percent validation.http://www.tera-vista.com Arch Angels Investment: $50,000

U.S. SPINE, INC.

US Spine® had a very productive 2009, launching four new product lines including the Preference™ 2 Complex Spine System, the Phantom™ Plus Interbody System, the Facet Gun™ Max and the Javelin™ MIS Locking Facet System. Both the Preference™ 2 Complex Spine System and Phantom™ Plus lines strengthen the company’s core product portfolio, while the Facet Gun™ Max and Javelin™ systems cement its place as the leader in Facet Technologies. Thanks to product development success in 2009, US Spine® has strong momentum and is poised to have an outstanding year with projected revenues in the $20 to $25 million range for fiscal 2010.www.us-spine.comArch Angels Investment: $5,900,000

Update on other companies in which the Arch Angels network has invested:

  • Gridlogix was acquired by Johnson Controls in 2009
  • GameRail ceased operations in 2008
  • Cervimark ceased operations in 2009